生物谷报道：Jan M. Agosti 和Sue J. Goldie在《新英格兰医学杂志》的这篇文章中说，一种新的疫苗可能防止发展中国家数以百万计的妇女死于宫颈癌——但是前提是它的价格合理。
科学家已经开发了一种能有效预防16型和18型人乳头瘤病毒（HPV）的疫苗，这种病毒导致了全部宫颈癌病例的3/4。
全世界每年有27.4万人死于宫颈癌，其中80%出现在发展中国家。这些作者说，在这些国家推广HPV疫苗的最大障碍是它的价格太高。
但是如果采用分级定价和补贴政策，诸如全球疫苗免疫联盟（GAVI Alliance）所提供的模式，可以让更贫穷的国家获得疫苗。
这些作者认为需要全球真正努力把这种挽救生命的疫苗带给发展中国家。他们还指出，每延迟5年就会导致另外150万到200万人死于宫颈癌。
这些作者还建议继续在低收入地区检查未接种疫苗妇女是否患有HPV 16、HPV 18以及其它类型HPV引起的癌症。
原始出处:
Introducing HPV Vaccine in Developing Countries — Key Challenges and Issues
Jan M. Agosti, M.D., and Sue J. Goldie, M.D., M.P.H.
More than any other cancer, cervical cancer reflects striking global health inequity. It is the second most common cancer among women worldwide, with about 493,000 new cases diagnosed annually (see map). Of 274,000 deaths due to cervical cancer each year, more than 80% occur in developing countries, and this proportion is expected to increase to 90% by 2020.1 Affecting relatively young women, it is the largest single cause of years of life lost to cancer in the developing world. The deaths of women who are in their most productive years have a devastating effect on the well-being of their families, resulting, for example, in decreases in school attendance and nutritional status among their children.
Age-Standardized Rates of New Cases of Cervical Cancer per 100,000 Women, 2002.
Numbers of cases for each continent represent the annual incidence of cervical cancer. Pie charts show the proportion of cases caused by HPV-16 or HPV-18. Data are from the Globocan 2002 database
A new quadrivalent human papillomavirus (HPV) vaccine has now been proved to be effective in preventing cervical intraepithelial neoplasia grade 2 and grade 3 caused by HPV types 16 and 18 (see reports by the FUTURE II Study Group on pages 1915–1927 and by Garland and colleagues on pages 1928–1943). According to meta-analyses, these two types of HPV account for an estimated 70% of all cervical cancers worldwide, representing a slightly higher fraction in developed regions (72 to 77%) than in less developed regions (65 to 72%).2 Longer follow-up will be required to establish the degree of protection against other oncogenic strains (including HPV types 31, 33, 35, 45, 52, and 58), but the preliminary data are encouraging. Long-term monitoring will determine the durability of protection and the need for booster immunization. This vaccine has been studied in 27,000 women in 33 countries and is licensed in more than 60 countries. Results from the bivalent HPV-16/HPV-18 vaccine demonstrate similar efficacy. These data constitute sufficient evidence to support global policy recommendations for the introduction of either HPV vaccine.
